The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...

More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.< ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea ...

Alvotech and Advanz Pharma announce positive EMA opinion for AVT06, a biosimilar to Eylea®, advancing access for eye disorder treatments in Europe.

SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

If the world feels out of control, dystopian, or even apocalyptic, it's possible to change course. The fate of the human species may be at stake!

Chang cites the case of single-agent Avastin, which produced negative results in early phase 3 trials as a second-line breast cancer therapy, but subsequently fared better in colorectal cancer and ...

“The approval of YESAFILI by Health Canada—the first biosimilar to EYLEA in Canada—is a proud moment for Biocon Biologics," said Shreehas Tambe, CEO and Managing Director of Biocon Biologics.